AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
CSL Ltd Shares Lag Behind ASX 200 Despite Sector Standing
June 27, 2025 03:16 PM AEST| By Team Kalkine MediaHighlights,CSL Ltd (ASX:CSL) shares trail peers despite strong sector fundamentals,Shareholder returns weighed down by earnings trends and acquisition impacts,Leading broker commentary highlights mixed performance across divisions,CSL Ltd (ASX:CSL),...
PYC Therapeutics (ASX:PYC) Pushes Forward with Clinical Trials for Rare Genetic Disorder
June 27, 2025 01:53 PM AEST| By Team Kalkine MediaHighlights,PYC-002 shows potential in addressing root cause of PMS,Preclinical results indicate strong gene expression restoration,Clinical trials set to begin in approximately 12 months,PYC Therapeutics (ASX:PYC), a biotechnology firm developing pre...
NeuroScientific (ASX:NSB) Secures StemSmart Technology, Charts Fresh Clinical Path
June 27, 2025 01:19 PM AEST| By Team Kalkine MediaHighlights,NeuroScientific Biopharmaceuticals acquires full ownership of Isopogen WA and StemSmart™ technology,Strategic board changes implemented to support future clinical expansion,Promising early results from StemSmart™ therapy for Crohn’s diseas...
FDA Greenlight Boosts Atmo Biosciences with Game-Changing Gut Health Innovation
June 27, 2025 12:36 PM AEST| By Team Kalkine MediaHighlights,Atmo receives FDA clearance for gas-sensing capsule.,Diagnostic device targets gastrointestinal motility disorders.,U.S. commercial launch expected in July 2025.,Atmo Biosciences (ASX:AT1) has achieved a major milestone with the U.S. Food...
Orthocell Marks US Milestone with Remplir Nerve Repair Debut
June 27, 2025 12:28 PM AEST| By Team Kalkine MediaHighlights,Orthocell (OCC) completes first US surgery using Remplir,Remplir targets $2.4B US nerve repair market,Distributor-led expansion fuels growth momentum,Orthocell (ASX:OCC), a regenerative medicine company, has taken a critical step forward i...
Imugene Commences Dosing in Neo-POLEM Phase II Trial for Colorectal Cancer Immunotherapy
June 27, 2025 12:06 PM AEST| By Team Kalkine MediaHighlights,Imugene,begins Phase II patient dosing for colorectal cancer immunotherapy,Neo-POLEM study explores pre-surgery treatment with PD1-Vaxx,Trial targets mismatch repair-deficient colorectal cancer subtype,In a significant development for canc...
Orthocell Marks US Milestone with First Surgery Using Remplir™ Nerve Repair Device
June 27, 2025 11:20 AM AEST| By Team Kalkine MediaHighlights,Orthocell,completes first US-based,Remplir,™ nerve repair surgery,Expanding US distributor network aids commercial rollout,Positioned for strong sales momentum through FY26,Orthocell Ltd (ASX:OCC) has reached a significant milestone in its...
CSL Shares in Focus: Is This ASX200 Healthcare Giant Still a Resilient Contender?
June 27, 2025 10:37 AM AEST| By Team Kalkine MediaHighlights,CSL (CSL) shares decline over 14% YTD in 2025,Healthcare sector shows resilience amid economic cycles,CSL’s business units continue to support long-term growth,CSL Limited (ASX:CSL), a key player in the Australian healthcare sector and a p...
Percheron Therapeutics (ASX:PER) Signs Global License Deal for HMBD-002, Eyes 2026 Trial Launch
June 26, 2025 02:08 PM AEST| By Team Kalkine MediaHighlights,Percheron secures global rights to promising cancer immunotherapy asset.,Plans underway for Phase II trial of HMBD-002 by 2026.,Deal includes up to US$287M in milestones plus royalties.,Percheron Therapeutics (ASX:PER) has taken a strategi...
Percheron Therapeutics Strikes Global Deal for Promising Cancer Drug
June 26, 2025 01:26 PM AEST| By Team Kalkine MediaHighlights,Percheron secures global rights for mid-stage cancer therapy HMBD-002,Clinical trials planned for 2026 with advanced immuno-oncology focus,Strategic pivot follows extensive search after prior asset setback,In a major development that marks...
Percheron’s Strategic Leap into Immuno-Oncology with VISTA Therapy Acquisition
June 26, 2025 01:16 PM AEST| By Team Kalkine MediaHighlights,Percheron secures global rights to develop cancer immunotherapy HMBD-002,The licensed drug targets VISTA, a novel checkpoint with promising potential,Phase II trials expected to commence in 2026 following successful Phase I,Melbourne-based...
Can ResMed (ASX:RMD) Shine in the ASX200 in 2025?
June 26, 2025 11:24 AM AEST| By Team Kalkine MediaHighlights,ResMed (RMD) shows solid financial growth with strong revenue and profit metrics,Valuation metrics indicate RMD shares are trading below historical averages,Net cash position and healthy returns reinforce the company's stability,ResMed (AS...
COH Shares: A Closer Look at This ASX200 Healthcare Leader
June 26, 2025 10:26 AM AEST| By Team Kalkine MediaHighlights,COH designs innovative hearing implants globally,Healthcare stocks offer resilient, sticky revenue,Valuation suggests COH trading below 5-year average,Cochlear Ltd (ASX:COH) has seen a slight uplift of 0.3% in its share price since the beg...
Singular Health Group Expands Market Footprint with New ASX Securities Listing
June 26, 2025 10:20 AM AEST| By Team Kalkine MediaHighlights,Singular Health Group adds 1.57 million new securities to ASX,Move supports strategic capital flexibility and expansion goals,Focus,remains,on digital innovation in medical imaging,Singular Health Group Ltd (ASX:SHG), a digital healthcare...
Why Sonic Healthcare (ASX:SHL) Is Still in the Spotlight on the ASX300
June 25, 2025 10:46 AM AEST| By Team Kalkine MediaHighlights,SHL shares reflect solid healthcare fundamentals,Sector supported by resilient demand trends,Valuation appears below historical average,The share price of Sonic Healthcare Ltd (ASX:SHL) has seen a modest decline of 4.2% since the beginning...
Biotron (ASX:BIT) Advances Hepatitis B Therapy with Positive Safety Milestone
June 24, 2025 04:07 PM AEST| By Team Kalkine MediaHighlights,Biotron completes initial safety trials for HBV therapy,Antiviral testing in preclinical models set to begin,Progress backed by recent funding round,Biotron (ASX:BIT), a clinical-stage biotechnology company, has achieved a significant mile...
Tryptamine Therapeutics Secures Ethics Approval for Psilocin BED Trial | ASX 200
June 23, 2025 02:43 PM AEST| By Team Kalkine MediaHighlights,Tryptamine Therapeutics gains approval to commence first-in-human trial for BED using TRP-8803,Study to assess safety and impact on BED and related psychiatric conditions,Patient recruitment underway with treatment scheduled to begin later...
Neurizon Therapeutics Unveils Promising Preclinical Findings for ALS Therapy
June 20, 2025 06:09 PM AEST| By Team Kalkine MediaHighlights,NUZ-001 shows promising blood-brain barrier penetration.,Strong preclinical evidence supports ALS treatment potential.,Reinforces Neurizon’s position in innovative neurological therapeutics.,Neurizon Therapeutics (ASX:NUZ) has taken a sign...
CSL Gains FDA Nod as ASX 200 Healthcare Faces Global Pressure
June 20, 2025 05:21 PM AEST| By Team Kalkine MediaHighlights,CSL Limited (ASX:CSL) receives FDA clearance for rare disease treatment,Healthcare stocks within the ASX 200 and ASX 100 indices reflect cautious sentiment,External trade and policy developments influence ASX 200 healthcare performance,CSL...
Orthocell’s Breakthrough in Nerve Repair Places It on the ASX200 Innovation Radar
June 20, 2025 03:40 PM AEST| By Team Kalkine MediaHighlights,Orthocell’s Remplir outperforms traditional suture-only nerve repair methods,Interim study results support rapid U.S. product rollout,Potential to impact ASX200 medical innovation landscape,Orthocell (ASX:OCC) has unveiled encouraging inte...
Advertise your brand on Kalkine Media